Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation - Concepedia

Concepedia

Publication | Open Access

Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

DOI Full Paper Access

225

Citations

27

References

2019

Year

Yan Xing, Nancy U. Lin, Matthew Maurer, Huiqin Chen, Armeen Mahvash, Ayşegül A. Şahin, Argun Akçakanat, Yisheng Li, Vandana G. Abramson, Jennifer K. Litton,

Breast Cancer Research

References

	Year	Citations

Page 1